HBV treatment indications and options

HBV Treatment Indications - When to Pull the Trigger

• Decision to treat hinges on HBeAg status, HBV DNA levels, ALT, and the degree of liver fibrosis.
• Treat ALL patients with cirrhosis, regardless of DNA/ALT levels.
• For indeterminate cases (e.g., normal ALT but high DNA), a liver biopsy or FibroScan helps assess fibrosis severity to guide the decision.

⭐ The primary goal of HBV treatment is to suppress HBV DNA replication to the lowest possible level to reduce the risk of progression to cirrhosis and hepatocellular carcinoma (HCC).

HBV Treatment Options - The Antiviral Arsenal

• First-Line Nucleos(t)ide Analogs (NAs): Potent viral suppression. 📌 'Eat Ten Eggs' (Entecavir, Tenofovir, E-antigen seroconversion).
  • Entecavir (ETV):
    • Mechanism: Guanosine nucleoside analog; inhibits HBV DNA polymerase.
    • Pros: High barrier to resistance, well-tolerated.
  • Tenofovir (TDF & TAF):
    • Mechanism: Adenosine nucleotide analog; inhibits HBV reverse transcriptase.
    • Pros: High potency, high barrier to resistance.
    • Cons: TDF associated with potential renal toxicity and ↓ bone mineral density.

⭐ Tenofovir alafenamide (TAF) is preferred over Tenofovir disoproxil fumarate (TDF) in patients with renal insufficiency or high risk of bone density loss.

• Pegylated Interferon-alfa (PEG-IFN):
  • Mechanism: Immunomodulatory; boosts host immune response to clear infected hepatocytes.
  • Pros: Finite treatment course (48 weeks), no resistance, higher rate of HBsAg clearance.
  • Cons: Subcutaneous injection, significant side effects (flu-like symptoms, fatigue, depression, cytopenias), contraindicated in decompensated cirrhosis.

Special Populations - Handling Curveballs

• Pregnancy:
  • Treat if HBV DNA >200,000 IU/mL to ↓ perinatal risk.

  ⭐ In pregnant patients with HBV DNA >200,000 IU/mL, antiviral therapy (typically Tenofovir TDF) is recommended from the third trimester until delivery to prevent perinatal transmission.

• HIV Co-infection:
  • ART regimen must include two agents active against both HIV and HBV (e.g., Tenofovir + Lamivudine/Emtricitabine).
• Decompensated Cirrhosis:
  • Treat all patients with any detectable HBV DNA to prevent further decompensation.
• Immunosuppression (e.g., chemotherapy, biologics):
  • Prophylactic antiviral therapy is crucial to prevent HBV reactivation.

High‑Yield Points - ⚡ Biggest Takeaways

• Treat chronic HBV in patients with active inflammation (↑ ALT) and high HBV DNA (>2,000 IU/mL).
• All patients with cirrhosis and detectable HBV DNA require treatment, regardless of ALT levels.
• First-line therapy uses potent nucleos(t)ide analogs (NAs) like Entecavir and Tenofovir.
• Pegylated interferon offers a finite treatment course but has significant side effects.
• The primary goal is lifelong viral suppression to prevent cirrhosis and hepatocellular carcinoma (HCC).
• Acute hepatitis B management is supportive unless it becomes fulminant.